Moderna's melanoma combination hit its efficacy endpoints, though payer economics for the therapy remain unresolved.

Novo Nordisk halved the US price of its weight-loss drug amid intensifying competition and pressure on GLP-1 pricing.

A new experimental Lilly obesity drug showed substantial weight loss in trial results, adding to the company's GLP-1 franchise.

Novo Nordisk said trial data confirmed weight loss for its obesity drug, a core part of its GLP-1 portfolio.

Xencor reported encouraging kidney cancer data for XmAb819 and plans a late-stage trial.

Viking Therapeutics' oral obesity strategy is the key focus for investors ahead of its Oct. 28 update.

Weekly insulin approval, analyst disagreement, and a buyback shaped the Novo Nordisk investment case.

Leads Biolabs reported 21.8-month median PFS in first-in-human RRMM data at ESMO 2026.

AbbVie won FDA approval for at-home Skyrizi starts in Crohn's disease.

Parabilis reported a 72.2% objective response rate for zolucatetide in desmoid tumors and set a Phase 3 plan.

Capricor's DMD therapy received Lancet backing ahead of an August FDA decision.

NovaBridge reported mature Phase 1b givastomig data supporting registrational development.

Lilly's early ovarian cancer study found disease controlled in every patient assessed.

Lycia raised $317 million in an IPO for inflammation drugs based on Nobel Prize-winning science.

J.P. Morgan projected the GLP-1 market in China, India, and Brazil could reach $22 billion by 2035.

Verastem shares drew attention after fresh VS-7375 data and alignment with FDA trial plans.

Compass Therapeutics published Phase 2/3 COMPANION-002 results for tovecimig and presented at ESMO 2026.

Responses to Lilly's experimental lung cancer combo lasted a median 14.5 months.